Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise

Dermato-Endocrinology

Volumn 3, Issue 3, 2011, Pages 130-135

  Sertznig, Pit ^a   Reichrath, Jörg ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Atopic dermatitis; Cancer; Dermatology; Inflammation; PPAR; Psoriasis; Scleroderma

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; CLOFIBRATE; DOCOSAHEXAENOIC ACID; DOXORUBICIN; FENOFIBRATE; GEMFIBROZIL; LIGAND; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROFECOXIB; ROSIGLITAZONE; TETRADECYLTHIOACETIC ACID; TRANSCRIPTION FACTOR; TROFOSFAMIDE; UNCLASSIFIED DRUG; ZILEUTON;

ACNE; ACTINIC KERATOSIS; APOPTOSIS; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; ENERGY BALANCE; EPIDERMIS; GENE CONTROL; HUMAN; INFLAMMATION; KERATINOCYTE; LIPID METABOLISM; MELANOMA; NONHUMAN; PSORIASIS; PSORIASIS VULGARIS; REVIEW; SCLERODERMA; SKIN CANCER; SKIN CELL; SKIN DISEASE; SKIN FIBROSIS; SKIN INFLAMMATION; WOUND HEALING;

EID: 80054026326     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.15025     Document Type: Review

References (91)

1. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993; 32:5598-604. (Pubitemid 23178525)
2. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000; 448:121-38. (Pubitemid 30139449)
3. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358:771-4.
4. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-50. (Pubitemid 30127149)
5. Boyd AS. Thiazolidinediones in dermatology. Int J Dermatol 2007; 46:557-63. (Pubitemid 46909394)
6. Sertznig P, Seifert M, Tilgen W, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 2008; 9:15-31. (Pubitemid 351993189)
7. Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet 2002; 3:199-209. (Pubitemid 34506588)
8. Schilling JA. Wound healing. Surg Clin North Am 1976; 56:859-74.
9. Serhan CN, Chiang N. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics. Rheum Dis Clin North Am 2004; 30:69-95. (Pubitemid 38234769)
10. Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, Hardt-Weinett K, et al. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 2001; 117:1430-6. (Pubitemid 34032769)
11. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta mutant mice. J Cell Biol 2001; 154:799-814. (Pubitemid 34292961)
12. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001; 15:3263-77. (Pubitemid 34008192)
13. Tan NS, Michalik L, Di-Poi N, Ng CY, Mermod N, Roberts AB, et al. Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO J 2004 23:4211-21. (Pubitemid 39546159)
14. Grose R, Werner S. An aPPARently protective mechanism for keratinocytes in wounded skin. Trends Mol Med 2002; 8:149-51. (Pubitemid 34297083)
15. Rivier M, Castiel I, Safonova I, Ailhaud G, Michel S. Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol 2000; 114:681-7. (Pubitemid 30227000)
16. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor- gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136:609-16. (Pubitemid 30304942)
17. Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J. Activation of PPARbeta/delta causes a psoriatis-like skin disease in vivo. PLoS One 2010; 5:9701.
18. Westergaard M, Henningsen J, Johansen C, Rasmussen S, Svendsen ML, Jensen UB, et al. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol 2003; 121:1104-17. (Pubitemid 37430980)
19. Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferator- activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 2006; 15:154-60.
20. Kuenzli S, Saurat JH. Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study 2003; 206:252-6.
21. Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134:1304-5.
22. Robertshaw H, Friedmann PS. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol 2005; 152:189-91.
23. Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, et al. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 2004; 123:305-12. (Pubitemid 38951825)
24. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPARgamma and immunoregulation: PPARgamma mediates inhibition of helper T cell responses. J Immunol 2000; 164:1364-71. (Pubitemid 30067250)
25. Rühl R, Dahten A, Schweigert FJ, Herz U, Worm M. Inhibition of IgE-production by peroxisome proliferator- activated receptor ligands. J Invest Dermatol 2003; 121:757-64. (Pubitemid 37239119)
26. Dahten A, Mergemeier S, Worm M. PPARgamma expression profile and its cytokine driven regulation in atopic dermatitis. Allergy 2007; 62:926-33. (Pubitemid 47037865)
27. Dahten A, Koch C, Ernst D, Schnöller C, Hartmann S, Worm M. Systemic PPARgamma ligation inhibits allergic immune response in the skin. J Invest Dermatol 2008; 182:2211-8.
28. Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferatoractivated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 2008; 144:84-8. (Pubitemid 351159393)
29. De Belilovsky C, Roo-Rodriguez E, Baudouin C, Menu F, Chadoutaud B, Msika P. Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similiar therapeutic response to topical steroids in atopic dermatitis. J Dermatolog Treat 2010; In press.
30. Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology 2001; 203:277-9. (Pubitemid 34045185)
31. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol 2004; 22:360-6. (Pubitemid 39535276)
32. Zouboulis CC, Degitz K. Androgen action on human skin - from basic research to clinical significance. Exp Dermatol 2004; 13:5-10. (Pubitemid 39654434)
33. Rosenfield RL, Deplewski D, Greene ME. Peroxisome proliferator-activated receptors and skin development. Horm Res 2000; 54:269-74. (Pubitemid 34701732)
34. Kim MJ, Deplewski D, Ciletti N, Michel S, Reichert U, Rosenfield RL. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development. Mol Genet Metab 2001; 74:362-9. (Pubitemid 33111918)
35. Zouboulis CC, Eady A, Philpott M, Goldsmith LA, Orfanos C, Cunliffe WC, Rosenfield R. What is the pathogenesis of acne? Exp Dermatol 2005; 14:143-52. (Pubitemid 40277582)
36. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006; 126:2002-9.
37. Lin Q, Ruuska SE, Shaw NS, Dong D, Noy N. Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 1999; 38:185-90. (Pubitemid 29035685)
38. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator- activated receptors in inflammation control. J Endocrinol 2001; 169:453-9. (Pubitemid 32536978)
39. Zouboulis CC, Nestoris S, Adler YD, Orth M, Orfanos CE, Picardo M, et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003; 139:668-70. (Pubitemid 36576390)
40. Alestas T, Ganceviciene R, Fimmel S, Müller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med 2006; 84:75-87. (Pubitemid 43099526)
41. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384:39-43.
42. Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol 2009; 1:188-92.
43. Zouboulis ChC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 2005; 210:36-8. (Pubitemid 39656717)
44. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140:37-50. (Pubitemid 38055920)
45. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117:557-67. (Pubitemid 46348510)
46. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-51. (Pubitemid 32096342)
47. Thannickal VJ, Toews GB, White ES, Lynch JP, 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004; 55:395-417. (Pubitemid 38316734)
48. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, et al. PPARgamma agonists inhibit TGF beta induced pulmonary myofibroblasts differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288:1146-53.
49. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008; 102:283-94. (Pubitemid 351271648)
50. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007; 9:136-43. (Pubitemid 46932720)
51. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009; 60:2822-9.
52. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin- induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009; 174:519-33.
53. Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology 2010; 49:259-63.
54. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5:419-29. (Pubitemid 38878045)
55. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006; 58:726-41. (Pubitemid 44833742)
56. Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression and therapy of cancer. J Cell Physiol 2007; 212:1-12. (Pubitemid 46876399)
57. Indra AK, Castaneda E, Antal MC, Jiang M, Messaddeq N, Meng X, et al. Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor a in epidermal keratinocytes. J Invest Dermatol 2007; 127:1250-60. (Pubitemid 46625143)
58. Michalik L, Desvergne B, Wahli W. Peroxisomeproliferator- activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4:61-70. (Pubitemid 38082154)
59. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-88. (Pubitemid 30650602)
60. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smoothmuscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393:790-3. (Pubitemid 28299490)
61. Müller-Decker K, Reinerth G, Krieg P, Zimmermann R, Heise H, Bayerl C, et al. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999; 82:648-56. (Pubitemid 29356962)
62. Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004; 151:837-45. (Pubitemid 39482118)
63. Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol Sci 2010; 113:27-36.
64. Nijsten T, Geluyckens E, Colpaert C, Lambert J. Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol 2005; 32:340-7. (Pubitemid 40547792)
65. Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, Hardt-Weinelt K, et al. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 2001; 117:1430-6. (Pubitemid 34032769)
66. Thuillier P, Anchiraico GJ, Nickel KP, Maldve RE, Gimenez-Conti I, Muga SJ, et al. Activators of peroxisome proliferator- activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog 2000; 29:134-42.
67. Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 2002; 1:357-63.
68. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274:9116-21. (Pubitemid 29164719)
69. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110:923-32.
70. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002; 277:23534-43. (Pubitemid 34952189)
71. Black HS, Herd JA, Goldberg LH, Wolf JE Jr, Thomby JI, Rosen T, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med 1994; 330:1272-5. (Pubitemid 24129960)
72. Berwick M, Wiggins C. The current epidemiology of cutaneous malignant melanoma. Front Biosci 2006; 11:1244-54.
73. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007; 17:117-27. (Pubitemid 46673905)
74. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4:748-59. (Pubitemid 37527210)
75. Mössner R, Schulz U, Krüger U, Middel P, Schinner S, Füzesi L, et al. Agonists of peroxisome proliferatoractivated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 2002; 119:576-82.
76. Kang HY, Chung E, Lee M, Cho Y, Kang WH. Expression and function of peroxisome proliferator- activated receptors in human melanocytes. Br J Dermatol 2004; 150:462-8. (Pubitemid 38446300)
77. Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP, et al. In vitro and in vivo antimelanoma effects of ciglitazone. J Invest Dermatol 2009; 129:1208-18.
78. Sertznig P, Dunlop T, Seifert M, Tilgen W, Reichrath J. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Res 2009; 29:3647-58.
79. Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via downregulation of Akt. Clin Cancer Res 2006; 12:3028-36. (Pubitemid 43837347)
80. Grabacka M, Placha W, Plonka PM, Pajak S, Urbanska K, Laidler P, Slominski A. Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 2004; 296:54-8. (Pubitemid 39024837)
81. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high density lipoprotein cholesterol intervention trial study. N Engl J Med 1999; 341:410-8. (Pubitemid 29362514)
82. Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, Dellavalle RP. Statins, fibrates and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006; 98:1538-46. (Pubitemid 44680905)
83. Liu Y, Meng Y, Li H, Li J, Fu J, Liu Y, et al. Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375. Med Oncol 2006; 23:393-402. (Pubitemid 44507149)
84. Denkins Y, Kempf D, Ferniz M, Nileshwar S, Marchetti D. Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. J Lipid Res 2005; 46:1278-84. (Pubitemid 43109842)
85. Cario-André M, Briganti S, Picardo M, Nikaido O, de Verneuil H, Taïeb A. Polyunsaturated fatty acids partially reproduce the role of melanocytes in the epidermal melanin unit. Exp Dermatol 2005; 14:194-201. (Pubitemid 40394203)
86. Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 2004; 64:1181-9. (Pubitemid 38176927)
87. Reichle A, Vogt T, Coras B, Terheyden P, Neuber K, Trefzer U, et al. Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 2007; 17:360-4. (Pubitemid 350084990)
88. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, et al. Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res 2009; 848645.
89. Wang Y, Li L, Jiang W, Yang Z, Zhang Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett 2006; 16:2974-7.
90. Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol 2009; 63:451-8.
91. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hemamalini S, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001; 7:3229-38. (Pubitemid 32963848)